# Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)

> **NCT05862545** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 250 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** BGF (budesonide/glycopyrrolate/formoterol fumarate)

## Key facts

- **NCT ID:** NCT05862545
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-01
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-05-31
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05862545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05862545, "Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05862545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*